Preliminary, top-line data show that Cologuard demonstrated 92 percent sensitivity for the detection of colorectal cancer and 42 percent sensitivity for the detection of pre-cancerous polyps, including 66 percent sensitivity for polyps equal to or greater than 2 centimeters. The test achieved a specificity of 87 percent during the trial.
Although these data meet the requirements in the SPA, they fall short of investors’ and the companies’ expectations from the phase-2 data. In particular, the specificity of only 87% is problematic for a test intended for the general (i.e. low-risk) population; it will lead to a large number of false positives for each true positive.
The sensitivity for pre-cancer of 42% is also disappointing insofar as finding polyps before they turn cancerous is one of the main goals of this kind of screening.
Al told, the DeeP-C data may be good enough for FDA approval, but commercial success is less certain.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.